The Role of Hepatitis B Core-Related Antigen.

Antiviral Agents / therapeutic use Biomarkers / blood Carcinoma, Hepatocellular / blood Hepatitis B Core Antigens / blood Hepatitis B e Antigens / blood Hepatitis B virus / physiology Hepatitis B, Chronic / blood Humans Liver Neoplasms / blood Liver Transplantation
HBV DNA chronic hepatitis B (CHB) covalently closed circular DNA (cccDNA) hepatitis B core-related antigen (HBcrAg) hepatitis B virus (HBV)

Journal

Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097

Informations de publication

Date de publication:
09 05 2019
Historique:
received: 02 04 2019
revised: 02 05 2019
accepted: 06 05 2019
entrez: 12 5 2019
pubmed: 12 5 2019
medline: 12 5 2019
Statut: epublish

Résumé

Hepatitis B virus (HBV) cannot be completely eliminated from infected hepatocytes due to the existence of intrahepatic covalently closed circular DNA (cccDNA). Serological biomarkers reflect intrahepatic viral replicative activity as non-invasive alternatives to liver biopsy. Hepatitis B core-related antigen (HBcrAg) is a novel biomarker that has an important role in chronic hepatitis B (CHB), because it correlates with serum HBV DNA and intrahepatic cccDNA. In clinical cases with undetectable serum HBV DNA or loss of HBsAg, HBcrAg still can be detected and the decrease in HBcrAg levels is significantly associated with promising outcomes for CHB patients. HBcrAg can predict spontaneous or treatment-induced hepatitis B envelope antigen (HBeAg) seroconversion, persistent responses before and after cessation of nucleos(t)ide analogues, potential HBV reactivation, HBV reinfection after liver transplantation, and risk of hepatocellular carcinoma progression or recurrence. In this review, the clinical applications of HBcrAg in CHB patients based on its virological features are described. Furthermore, new potential therapeutic anti-HBV agents that affect intrahepatic cccDNA are under development, and the monitoring of HBcrAg might be useful to judge therapeutic effects. In conclusion, HBcrAg might be a suitable surrogate marker beyond other HBV markers to predict the disease progression and treatment responses of CHB patients.

Identifiants

DOI: 10.3390/genes10050357 PMID: 31075974 PMC: PMC6562807
pubmed: 31075974
pii: genes10050357
doi: 10.3390/genes10050357
pmc: PMC6562807
pii:
doi:

Substances chimiques

Antiviral Agents 0
Biomarkers 0
Hepatitis B Core Antigens 0
Hepatitis B e Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

Funding: This research was supported by AMED under Grant Number JP19fk0310101h0003.

Références

Microb Cell. 2016 Sep 05;3(9):420-437
pubmed: 28357379
Aliment Pharmacol Ther. 2016 Jun;43(12):1253-61
pubmed: 27117732
J Viral Hepat. 2003 Jul;10(4):324-30
pubmed: 12823601
Gastroenterology. 2008 Oct;135(4):1192-9
pubmed: 18722377
Liver Int. 2017 Jul;37(7):995-1001
pubmed: 27992681
Hepatol Res. 2019 Mar;49(3):271-283
pubmed: 30358027
Liver Int. 2017 Aug;37(8):1138-1147
pubmed: 27992664
Best Pract Res Clin Gastroenterol. 2015 Dec;29(6):907-17
pubmed: 26651252
Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):281-289
pubmed: 28774410
Hepatology. 2004 Sep;40(3):727-37
pubmed: 15349913
Gastroenterology. 2006 Mar;130(3):678-86
pubmed: 16530509
Clin Microbiol Infect. 2014 Nov;20(11):1173-80
pubmed: 24975365
J Clin Microbiol. 2007 Dec;45(12):3942-7
pubmed: 17942661
Nucleic Acids Res. 2017 Feb 17;45(3):1469-1478
pubmed: 28180327
Hepatol Res. 2006 Dec;36(4):272-6
pubmed: 16971173
Hepatology. 2016 Jan;63(1):261-83
pubmed: 26566064
Clin Res Hepatol Gastroenterol. 2019 Jun;43(3):301-309
pubmed: 30497844
World J Hepatol. 2018 Sep 27;10(9):603-611
pubmed: 30310538
Nat Biotechnol. 2007 Jul;25(7):778-85
pubmed: 17603475
J Clin Microbiol. 2019 Jan 2;57(1):
pubmed: 30355757
J Gastroenterol Hepatol. 2013 Jul;28(7):1217-22
pubmed: 23432697
Cell. 1986 Nov 7;47(3):451-60
pubmed: 3768961
Hepatol Int. 2011 Mar 25;5(4):918-926
pubmed: 21484119
Genes (Basel). 2018 Sep 27;9(10):
pubmed: 30262738
J Viral Hepat. 2019 May;26(5):586-595
pubmed: 30632235
Antiviral Res. 2017 Aug;144:205-215
pubmed: 28647474
Liver Int. 2006 Feb;26(1):90-6
pubmed: 16420514
Nat Methods. 2011 Jan;8(1):74-9
pubmed: 21131970
J Infect Dis. 2016 Apr 1;213(7):1096-106
pubmed: 26621908
Antivir Ther. 2019;24(2):105-115
pubmed: 30511941
J Clin Microbiol. 2002 Feb;40(2):439-45
pubmed: 11825954
Hepatology. 2016 May;63(5):1517-27
pubmed: 26426978
Elife. 2012 Nov 13;3:
pubmed: 25409679
Biochemistry (Mosc). 2014 Feb;79(2):111-23
pubmed: 24794726
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
Microbiol Mol Biol Rev. 2000 Mar;64(1):51-68
pubmed: 10704474
J Biol Chem. 2005 Jun 10;280(23):21713-9
pubmed: 15814524
Antiviral Res. 2015 Jun;118:110-7
pubmed: 25843425
J Gastroenterol. 2017 Mar;52(3):366-375
pubmed: 27422771
Clin Chim Acta. 2018 Nov;486:237-244
pubmed: 30025756
Clin Mol Hepatol. 2016 Dec;22(4):423-431
pubmed: 28081591
Aliment Pharmacol Ther. 2018 Jan;47(1):43-54
pubmed: 29035003
J Viral Hepat. 2017 Aug;24(8):654-661
pubmed: 28185363
J Clin Virol. 2018 Feb - Mar;99-100:71-78
pubmed: 29353073
J Hepatol. 2016 Jul;65(1):48-56
pubmed: 27034253
Transplant Proc. 2004 Apr;36(3):535-8
pubmed: 15110584
Hepatol Res. 2019 Jan;49(1):51-63
pubmed: 30350374
J Hepatol. 2008 Oct;49(4):652-7
pubmed: 18715666
Genes Cells. 2016 Nov;21(11):1253-1262
pubmed: 27659023
J Virol Methods. 2016 Sep;235:92-98
pubmed: 27230224
J Viral Hepat. 2018 Aug;25(8):886-893
pubmed: 29532589
Ann Intern Med. 2007 Jul 3;147(1):58-61
pubmed: 17606962
Liver Int. 2016 Jun;36(6):827-36
pubmed: 26678018
JAMA Surg. 2014 Jun;149(6):519-27
pubmed: 24696192
J Viral Hepat. 2019 May;26(5):568-575
pubmed: 30576048
Viruses. 2009 Sep;1(2):185-209
pubmed: 21994545
J Med Virol. 2006 Jan;78(1):68-73
pubmed: 16299733
J Hepatol. 2017 Feb;66(2):275-281
pubmed: 27639844
Mol Ther Nucleic Acids. 2014 Aug 19;3:e186
pubmed: 25137139
FEBS J. 2017 Nov;284(21):3550-3572
pubmed: 28457020
Sci Rep. 2017 Dec;7(1):173
pubmed: 28282964
J Viral Hepat. 2016 Nov;23(11):905-911
pubmed: 27375231
Gut Liver. 2019 Nov 15;13(6):589-595
pubmed: 30919601
J Formos Med Assoc. 2015 Oct;114(10):901-9
pubmed: 26184565
J Hepatol. 2008 Feb;48(2):335-52
pubmed: 18096267
J Clin Microbiol. 2013 Nov;51(11):3484-91
pubmed: 23946517
J Hepatol. 2019 Apr;70(4):615-625
pubmed: 30529504
Am J Gastroenterol. 2016 Dec;111(12):1788-1795
pubmed: 27644733
JAMA. 2006 Jan 4;295(1):65-73
pubmed: 16391218
J Gastroenterol Hepatol. 2005 Nov;20(11):1726-30
pubmed: 16246193
J Hepatol. 2013 Mar;58(3):427-33
pubmed: 23123221
Gastroenterology. 2010 May;138(5):1747-54
pubmed: 20114048
Hepatology. 2001 Jul;34(1):194-203
pubmed: 11431751
Antiviral Res. 2015 Sep;121:97-108
pubmed: 26129970
Emerg Microbes Infect. 2014 Sep;3(9):e64
pubmed: 26038757
J Gastroenterol. 2016 Aug;51(8):830-9
pubmed: 26687058
Lancet Infect Dis. 2002 Jul;2(7):395-403
pubmed: 12127351
Hepatol Res. 2017 Jul;47(8):747-754
pubmed: 27577976
Nucleic Acid Ther. 2012 Dec;22(6):380-90
pubmed: 23181701
J Biomol Screen. 2013 Apr;18(4):378-87
pubmed: 23042077
Antivir Ther. 2008;13(1):57-66
pubmed: 18389899
Mol Plant. 2013 Sep;6(5):1384-7
pubmed: 23718948
Hepatology. 2013 Feb;57(2):441-50
pubmed: 22941922
Antiviral Res. 2018 Oct;158:135-142
pubmed: 30031759
World J Gastroenterol. 2013 Oct 21;19(39):6515-22
pubmed: 24151375
Mol Ther. 2013 May;21(5):973-85
pubmed: 23439496
Hepatol Res. 2014 Jan;44 Suppl S1:1-58
pubmed: 24397839
Am J Transplant. 2003 Mar;3(3):250-8
pubmed: 12614278
Intern Med. 2009;48(18):1577-83
pubmed: 19755758
Clin Microbiol Infect. 2015 Jun;21(6):606.e1-10
pubmed: 25700889
Hepatol Res. 2015 Dec;45(12):1195-202
pubmed: 25594111
J Viral Hepat. 2018 Nov;25(11):1226-1235
pubmed: 30187603
Chin Med J (Engl). 2016 20th Sep;129(18):2212-9
pubmed: 27625094
Virol J. 2013 Jul 20;10:239
pubmed: 23870415
N Engl J Med. 2004 Mar 11;350(11):1118-29
pubmed: 15014185
Aliment Pharmacol Ther. 2019 Jan;49(1):107-115
pubmed: 30450681
Hepatol Int. 2012 Mar 13;7(1):98-105
pubmed: 24014110
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Hepatology. 2019 Apr;69(4):1816-1827
pubmed: 30362148
J Med Virol. 2009 Jan;81(1):27-33
pubmed: 19031469
Aliment Pharmacol Ther. 2019 Feb;49(4):457-471
pubmed: 30663078
Sci Transl Med. 2017 Sep 27;9(409):
pubmed: 28954926
J Gastroenterol Hepatol. 2015 Jun;30(6):977-83
pubmed: 25689418
J Hepatol. 2015 May;62(5):1092-9
pubmed: 25445399
J Hepatol. 2005 May;42(5):760-77
pubmed: 15826727
Hepatol Int. 2016 Jan;10(1):99-101
pubmed: 26732689
PLoS One. 2019 Feb 22;14(2):e0212559
pubmed: 30794632
Hepatol Res. 2007 Aug;37(8):661-6
pubmed: 17584261
Expert Rev Gastroenterol Hepatol. 2016 Jun;10(6):697-707
pubmed: 26799653

Auteurs

Takako Inoue (T)

Department of Clinical Laboratory Medicine, Nagoya City University Hospital, Nagoya 467-8602, Japan. clinoue@med.nagoya-cu.ac.jp.

Yasuhito Tanaka (Y)

Department of Clinical Laboratory Medicine, Nagoya City University Hospital, Nagoya 467-8602, Japan. ytanaka@med.nagoya-cu.ac.jp.
Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan. ytanaka@med.nagoya-cu.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › The Role of Hepatitis B Core-Related Antigen.
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › The Role of Hepatitis B Core-Related Antigen.
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › The Role of Hepatitis B Core-Related Antigen.
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Antigènes d'hépatite virale › Antigènes de l'hépatite virale B › Antigènes de la nucléocapside du virus de l'hépatite virale B › The Role of Hepatitis B Core-Related Antigen.
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Antigènes d'hépatite virale › Antigènes de l'hépatite virale B › Antigènes e du virus de l'hépatite virale B › The Role of Hepatitis B Core-Related Antigen.
questionsmedicales.fr › Virus › Virus de l'hépatite › Hepadnaviridae › Orthohepadnavirus › Virus de l'hépatite B › The Role of Hepatitis B Core-Related Antigen.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Hépatite chronique › Hépatite B chronique › The Role of Hepatitis B Core-Related Antigen.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Role of Hepatitis B Core-Related Antigen.
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › The Role of Hepatitis B Core-Related Antigen.
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation de tissu › Transplantation hépatique › The Role of Hepatitis B Core-Related Antigen.